Table 3.
Efficacy and safety of 70mg erenumab in patients with ≥ 2 prior treatment failures.
| Outcomes | Erenumab 70 mg Group (n=49) | Placebo Group (n=27) | Number of Trials Included (Total Patients) | Combined Risk Ratio or Mean Difference (95% CI) | I2 |
|---|---|---|---|---|---|
| MMD | -1.8 (3.09), n=49 | -0.9 (3.29), n=27 | 1 (n=76) | -0.9 (-2.41 to 0.61) # | NA |
| MSMD | -1.1 (2.46), n=49 | -1 (2.38), n=27 | 1 (n=76) | -0.1 (-1.23 to 1.03) # | NA |
| 50% response rate | 13/49 (26.53%) | 4/27 (14.81%) | 1 (n=76) | 1.79 (0.65 to 4.95) * | NA |
| 75% response rate | 7/49 (14.29%) | 1/27 (3.7%) | 1 (n=76) | 3.86 (0.5 to 29.72) * | NA |
| AE | 33/49 (67.35%) | 19/27 (70.37%) | 1 (n=76) | 0.96 (0.7 to 1.31) * | NA |
| SAE | 2/49 (4.08%) | 0/27 (0%) | 1 (n=76) | 11.59 (0.02 to 6481.06) * | NA |
Outcome data are mean (SD) or n/N (%). NA= not applicable; MMD=Monthly Migraine Days; MSMD=Monthly Acute Migraine-Specific Medication Treatment Days; AE=Adverse Events; SAE=Serious Adverse Events; CI=Confidence Interval. *Risk ratio (binary outcomes). #Mean difference (quantitative outcomes).